Global Health Commercialization & Funding Roundtable: Panel III: TB Vaccines
Duration: 1 hour 1 min 28 secs
Share this media item:
Embed this media item:
Embed this media item:
About this item
| Description: |
This is the third panel of the Cambridge Global Health Commercialization & Roundtable open-day conference April 20, 2012. This panel focuses on innovation in TB vaccines.
- Moderator: Ann Ginsberg, Vice President of Scientific Affairs, AERAS - Adam Stoten, Deputy General Manager, Oxford Emergent Tuberculosis Consortium (OETC) - Zhongming Li, Founder and CEO, Shanghai H&G Biotechnology - Suresh Jadhav, Executive Director, Serum Institute of India Ltd Introduction offered by GHCF facilitator Diana Pirjol. |
|---|
| Created: | 2012-04-27 16:34 |
|---|---|
| Collection: | IfM Research |
| Publisher: | University of Cambridge |
| Copyright: | Institute for Manufacturing |
| Language: | eng (English) |
| Keywords: | Global health; vaccines; Resource providers; Private sector; Partnerships; |
| Abstract: | Panel III discussed the contribution of partnerships between entrepreuneurs in TB vaccine development and public-private funders in prevention. The panel moderator, AERAS’ representative, discussed the need for new TB vaccines, and how AERAS and various entrepreneurs are positioned to address this need in the larger innovation ecosystem. OETC was formed in 2008 as a joint venture between Oxford University and Emergent BioSolutions. The speaker from OETC illustrated what is needed to ensure the success of MVA85A vaccine during clinical development. The H&G Biotechnology panelist summarised how the Chinese government provided the funding and resources for him to conduct the phase I trial of Ag85a vaccine. Finally, the representative from the Serum Institute of India discussed the role of collaboarive partners in developing the safe and efficacious VPM1002.
The podcast is being presented as part of the Cambridge Global Health Commercialization & Funding Roundtable: www.bit.ly/ghcfroundtable |
|---|---|